RBRX.F Stock Overview
Rhino Biotech Limited intends to develop plant and fungi derived nutraceuticals, and preventative and curative biopharmaceuticals.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rhino Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -100.00% |
| 5 Year Change | -99.98% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| RBRX.F | US Oil and Gas | US Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | 0.7% |
| 1Y | n/a | 15.9% | 23.9% |
Return vs Industry: Insufficient data to determine how RBRX.F performed against the US Oil and Gas industry.
Return vs Market: Insufficient data to determine how RBRX.F performed against the US Market.
Price Volatility
| RBRX.F volatility | |
|---|---|
| RBRX.F Average Weekly Movement | n/a |
| Oil and Gas Industry Average Movement | 4.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RBRX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RBRX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Nick Baxter | ir.rhinobiotech.com |
Rhino Biotech Limited intends to develop plant and fungi derived nutraceuticals, and preventative and curative biopharmaceuticals. The company was formerly known as Eurasia Energy Limited and changed its name to Rhino Biotech Limited in September 2021. Rhino Biotech Limited was incorporated in 2003 and is based in South Hill, Anguilla.
Rhino Biotech Limited Fundamentals Summary
| RBRX.F fundamental statistics | |
|---|---|
| Market cap | US$31.00 |
| Earnings (TTM) | -US$21.23k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs RBRX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RBRX.F income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.23k |
| Earnings | -US$21.23k |
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RBRX.F perform over the long term?
See historical performance and comparison